HBS Alumni Angels
Angel Group/Syndicate
Active
San Rafael, United States
28
1M
25
1.75
4
0.07
2
- Stages of investment
- Areas of investment
Summary
In 2007 was created HBS Alumni Angels, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Allston. The company was established in North America in United States.
This organization was formed by Sean Jacobsohn, Tom Cervantez.
The typical startup value when the investment from HBS Alumni Angels is 1-5 millions dollars. Comparing to the other companies, this HBS Alumni Angels performs on 21 percentage points less the average number of lead investments. The usual things for fund are deals in the range of 1 - 5 millions dollars. The fund is constantly included in 2-6 deals per year. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. Considering the real fund results, this Corporate Investor is 4 percentage points less often commits exit comparing to other organizations. The top amount of exits for fund were in 2017.
Among the most successful fund investment fields, there are Analytics, Internet. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Capillary Biomedical, Cognovi Labs, SixPlus. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the HBS Alumni Angels, startups are often financed by Tech Coast Angels, New York Angels, CanopyBoulder. The meaningful sponsors for the fund in investment in the same round are New York Angels, Tech Coast Angels, Sand Hill Angels. In the next rounds fund is usually obtained by Sand Hill Angels, New York Angels, Leorsa Innovations.
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 28
- Lead investments
- 4
- Exits
- 2
- Rounds per year
- 1.75
- Follow on index
- 0.07
- Investments by industry
- Health Care (6)
- Software (4)
- Internet (4)
- Medical (4)
- Education (3) Show 76 more
- Investments by region
-
- United States (24)
- United Kingdom (1)
- India (1)
- Brazil (1)
- Peak activity year
- 2014
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Avg. valuation at time of investment
- 3M
- Group Appearance index
- 0.96
- Avg. company exit year
- 4
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Advanced Cancer Therapeutics | 01 Jul 2010 | Biotechnology, Drug Discovery, Manufacturing, Life Science, Therapeutics | Early Stage Venture | 10M | United States, Kentucky, Louisville |
Front Range Biosciences | 20 Sep 2017 | Biotechnology, Medical, Life Science, Agriculture, Cannabis | Seed | 3M | United States, Boulder, Colorado |
Trak | 25 Jun 2014 | Biotechnology, Health Care, Health Diagnostics, Wellness | Seed | 1M | United States, California |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.